You just read:

Pfizer's Newly Approved Once-Daily Xeljanz XR Is Unlikely To Expand Overall Brand Use According To The Latest Rheumatology Report From Spherix Global Insights

News provided by

Spherix Global Insights

Apr 20, 2016, 08:42 ET